However, CD57+ CD8+ T cells in the periphery show clonal expansion with the overlap of the TCR repertoire of tumor-infiltrating T cells with favorable response to ICI in cancer patients (Fehlings et al., 2022), indicating that these CD57+ CD8+ T cells may have a highly active phenotype in ICI-treated individuals. The gene discussed is B3GAT1; the disease is cancer.